The Rare Disease Company Coalition (RDCC) is asking the Trump administration to go further in excluding treatments for rare disease patients from tariffs under Section 232 of the Trade Expansion Act ...

Public health stakeholders say they’re alarmed by reports that President Trump may release an executive order to establish a White House board that would review all incoming grants at National ...

Congress should get rid of the No Surprises Act’s (NSA) federal arbitration process for elective care and either eliminate or overhaul it for emergency services, Paragon Health Institute says in a ...

At least 85 public health groups, universities and pharmaceutical companies are asking Senate and House leadership to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA), the law ...

Democrats should purse permanent telehealth legislation within a year if they regain control of the House in the midterm elections, a health care working group recommends in a memo to House Minority ...

HHS' Office of Inspector General plans to investigate how 503B outsourcing facilities and hospitals produce and use compounded sterile drugs and how many of them voluntarily register with FDA.

Two former GOP health care lawmakers are warning the White House that rising infectious disease rates coupled with the administration’s mixed messaging on vaccines are a “self-inflicted wound” that ...

Health policy stakeholders and former FDA officials are backing a group of bipartisan drug development reforms they say could boost domestic clinical research and expand patient access to treatments, ...

A new group of hospitals is rallying for the United States District Court for the District of Maine to once again block the government from implementing a pilot program that will replace upfront ...

FDA on Wednesday (Oct. 14) launched a Rare Disease Framework Initiative that it says will reform the development of rare disease treatments by considering each disease’s specific patient population ...

FDA has formally asked the White House Office of Management and Budget (OMB) to approve an “interim access policy” that could create a temporary pathway for state-licensed pharmacies to compound ...

An FDA advisory committee panel was divided in its consideration of GRAIL’s Galleri multicancer blood test, with members impressed by the test’s ability to detect cancers in patients who are ...